Epigenetic Therapy for Epithelioid Sarcoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32302562.
- Also identified by DOI 10.1016/j.cell.2020.03.042.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tazemetostat is the first epigenetic therapy to gain FDA approval in a solid tumor. This lysine methyltransferase inhibitor targets EZH2, the enzymatic subunit of the PRC2 transcriptional silencing complex. Tumors with mutations in subunits of the SWI/SNF chromatin remodeling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.
Medical subject headings
- Benzamides
- Epigenesis, Genetic
- Pyridones
- Sarcoma